An observational study in Diabetic Retinopathy, sponsored by Tameside General Hospital. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-02.
Sponsored by Tameside General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Diabetic Retinopathy with a site in United Kingdom — 6 open to participants now, 7 under way, 2 of them phase 3. Diabetic Retinopathy · United Kingdom.
Among the 41 studies in Diabetic Retinopathy with a site in United Kingdom, this one is the only one that started in 2022, is one of 9 observational ones, and was the 32nd registered.
779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
Browse Diabetic Retinopathy studies →6 of the 41 studies in Diabetic Retinopathy with a site in United Kingdom are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Argentina and 1 more country
Ages 18+
Swansea Bay University Health Board · Sites in United Kingdom
Ages 18+
Hywel Dda Health Board · Sites in United Kingdom
Ages 18–80
Hywel Dda Health Board · Sites in United Kingdom
Ages 18+ · Healthy volunteers
Boehringer Ingelheim · Sites in United Kingdom, United States, Germany and 6 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 14 · Phase 3 9 · Phase 4 4
First in 1999; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 410 is above the median of 172 across 263 observational studies indexed under Diabetic Retinopathy.
Median enrollment 137 across the 32 interventional studies, 200 across the 9 observational. Of the 32 that completed or were terminated, 12 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 41 have an industry lead sponsor. The 10 most frequent:
Tameside General Hospital is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Tameside General Hospital has 1 study filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetic Retinopathy with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07923292Swansea Bay University Health BoardTo Investigate the Feasibility and Acceptability of Trained Non-medical Professionals Performing Laser Treatment for Proliferative Diabetic Retinopathy (PDR), and the Potential Impact on Service Capacity. Assess Feasibility of Conducting a Full Trial Comparing Trained ECPs With Ophthalmologists | 2026-12 |
| NCT06321302Boehringer IngelheimA Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy | 2027-03-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies in Diabetic Retinopathy with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The prevalence of diabetic retinopathy (DR) in the UK is on the rise. Within 20 years of diabetes diagnosis, nearly all people with type 1 and almost two thirds of people with type 2 diabetes (60%) have some degree of DR. NHS guidelines mandate annual DR screening in all patients aged 12 and above to prevent complications of DR. Screening for DR in England involves labour-intensive manual grading of retinal images through the teleophthalmology platform. Automated retinal image analysis systems with the use of artificial intelligence (AI) may offer an alternative to manual grading.
The purpose of this study is to evaluate the performance of a portable, hand-held fundus camera with integrated artificial intelligence for diabetic retinopathy screening by comparing it against the current standard i.e diagnosis provided by trained human graders evaluating the standard photographs/ophthalmologists.
Study will enroll diabetic patients (new and established) meeting the inclusion criteria and who would provide an informed consent to participate in the study. This would include subjects who visit the endocrinology clinic and had either their retina evaluated by a teleophthalmology consult or visited the ophthalmology clinic for an indirect ophthalmoscopic fundus evaluation in the past 3 months. Subjects whose fundus has been recently evaluated in the past 3 months will also be re-called to the endocrinology clinic to get a fundus image captured on the Remidio NM FOP-10 device. Images will be captured by an operator who will be provided training in using the device prior to the study.
Non-mydriatic fundus images are captured using a pre-defined imaging protocol. One disc centered and one macula centred 45 deg image is taken for each eye. The images are then submitted to an AI system for analysis that runs locally on the Remidio FOP. An initial image quality assessment is performed by the AI. If the image is of sufficient quality then the AI will give an output of either 'signs of DR detected' (that would include moderate NPDR, severe NPDR, PDR and/or DME present) or no signs of diabetic retinopathy detected (that would include no DR, mild DR, absence of DME). If the image is of insufficient quality, then the operator makes 2 more attempts using the same imaging protocol. The images that are output as insufficient quality will be noted. All subjects who have provided consent for dilation are then instilled with a single drop of 1% tropicamide solution. After 20 mins, mydriatic 2 field (one disc centered and one macula centered) fundus images are captured and submitted to the AI for analysis along the same lines of non-mydriatic imaging. If the image is of insufficient quality then the operator makes 2 more attempts using the same imaging protocol. The images that are output as insufficient quality will be noted.
De-identified patient data including age, gender, ethnicity and lens status (Cataract grade, pseudophakia, aphakia) along with the final diagnosis made by a certified grader/ophthalmologist during clinical examination/teleophthalmology are retrieved from the NHS database. This DR diagnosis will act as a reference standard against which the AI output will be compared.
Data entry of subjects will be performed by approved trained Site Personnel. The de-identified data is stored onto an electronic data capture system (EDC). Approved Site Personnel will have a user specific log-in name and password to access the electronic data capture (EDC) system in order to enter study data. The principal investigator will ensure that all aspects of the study are complied with. The study will be conducted in accordance with applicable regulatory requirements and established rules for Good Clinical Practice (GCP).
Individuals with established diabetes mellitus presenting to GPs clinic for routine clinical care
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Colour fundus photography
Fundus images will be captured before and after administration of mydriatic agent
Also known as: Instillation of mydriatic eye drops
Sensitivity and Specificity of the AI in detecting any grade of diabetic retinopathy in those with established diabetes mellitus (DM)
Time frame: 4 months
To assess the positive predictive value, negative predictive value of AI in detecting any grade of DR
Time frame: 4 months
To assess the sensitivity to identify sight-threatening diabetic retinopathy (STDR defined as severe NPDR or more severe disease and/or the presence of DME ie grades U, M1, R2 or R3)
Time frame: 4 months
To compare the diagnostic ability of the AI in mydriatic and non-mydriatic eyes
Time frame: 4 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2022 to primary completion in Aug 2022, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tameside General Hospital